Evan Jones, Chairman and CEO
Mr. Jones is the Chairman and CEO of OpGen and also is the Managing Member of jVen Capital, LLC, a life sciences investment company. Prior to forming jVen Capital, he was co-founder, Chairman and CEO of Digene Corporation, a publicly traded biotechnology company focused on women’s health and molecular diagnostic testing. He is a Board Member of Fluidigm, Inc., Foundation Medicine, Inc., and Veracyte, Inc. Mr. Jones is Vice-Chairman of the Board of the Children’s National Medical Center and a Board Member of the Children’s Research Institute.
Mr. Jones received a B.A. degree from the University of Colorado and an M.B.A. from The Wharton School, University of Pennsylvania.
Brian G. Atwood, Director
Mr. Atwood is President and CEO as well as a co-founder of Cell Design Labs, a new company focused on developing the human cell engineering technology from the UC San Francisco lab of Wendell Lim. He is also a co-founder and Managing Director at Versant Ventures, a leading healthcare-focused venture capital firm, where he serves as a Managing Director. He has more than 15 years of operating experience in the biotechnology industry.
Prior to launching his career in venture capital, Mr. Atwood was Founder, President and Chief Executive Officer of Glycomed, a publicly traded biotechnology company. He also currently serves as a Board member at the private company Atreca as well as the public companies PhaseRx (PZRX), and Clovis Oncology, Inc. (CLVS).
Mr. Atwood received a BS in Biological Sciences from the University of California, Irvine, an MS in Ecology from the University of California, Davis, and an MBA from Harvard Business School.
Harry J. D’Andrea, Director
Mr. D’Andrea is managing general partner of Valhalla Partners, a venture capital firm, a position he has held since January 2012. He previously served as administrative general partner of Valhalla Partners since June 2002, and was a co-founder of Valhalla Partners in 2002. From June 1999 to February 2002, Mr. D’Andrea was Chief Financial Officer of Advanced Switching Communications, Inc., a Nasdaq-listed company that completed its IPO in October 2000. Prior thereto from 1989 to 1999 he held senior financial positions with a number of privately held and public companies. Mr. D’Andrea is currently a director of four privately held companies and has served on the boards of two publicly traded companies in the past.
He received his B.A. in Foreign Service from The Pennsylvania State University and his MBA from Drexel University.
Timothy J.R. Harris, Ph.D., Director
Dr. Harris is a science and business leader with nearly 40 years of experience guiding and leading laboratory work and scientists in a range of molecular research areas.
He is a molecular biologist and biochemist, and is currently a Venture Partner with SV Life Sciences and acting EVP R&D at Bioverativ. He was until March 2016, the SVP for Precision Medicine at Biogen. He was before that SVP of Translational Medicine at Biogen Idec. Until 2011, he was the Chief Technology Officer (CTO) and Director of the Advanced Technology Program (ATP) at SAIC-Frederick, Inc. in Maryland which operates the National Cancer Institute’s leading center for cancer and AIDS research (now Frederick National Laboratory operated by Leidos Inc.,).
He has served as President and Chief Executive Officer (CEO) of Novasite Pharmaceuticals, and he founded SGX Pharmaceuticals in 1999 (formerly Structural Genomix), where he built the company to more than 130 employees, raised $85M in capital, and generated more than $20M in revenue during six years as CEO before it was sold to Eli Lilly. Before founding SGX, Dr. Harris was Senior Vice President, Research and Development at Sequana/Axys. He began his scientific career working on animal viruses such as foot & mouth disease and was one of the first molecular biologists (1981) at Celltech (now UCB Pharma) in the United Kingdom. He subsequently spent five years at Glaxo Group Research as Director of Biotechnology from 1989 to 1993.
He is currently on the Board of Directors of Opgen (Nasdaq: OPGN) and is a visiting Professor at Columbia University, New York.
Laurence R. McCarthy, Ph.D., Director
Dr. McCarthy joined Ampersand Capital Partners in 2007 as an Operating Partner and currently serves as a Director of Genoptix Medical Laboratories, Bako Pathology, and Dynex, He has also served as Executive Chairman of Viracor-IBT Laboratories, Executive Chairman of Bako Pathology, Executive Chairman of PrimeraDx and as a Director of ATS and Magellan.
He built Focus Diagnostics from a $2 million business to a leading esoteric lab with over $80 million in revenues by the time of its acquisition by Quest Diagnostics in 2006, serving over time as CEO, Chairman and Chief Technology Officer. Prior to Focus, Dr. McCarthy served in various senior management positions at Boehringer Mannheim Diagnostics and at Becton Dickinson and Co.
He holds a Ph.D. in Microbiology from the University of New Hampshire and served on the faculties of Cornell University School of Medicine, the University of North Carolina School of Medicine and the Johns Hopkins University School of Medicine.
David M. Rubin, Ph.D., Director
Dr. Rubin is a Managing Director in Merck’s Global Health Innovation fund with a primary focus area on precision medicine. Dr. Rubin has invested in molecular diagnostics, point-of-care diagnostics, imaging, and therapeutic device companies that address unmet needs in oncology, infectious disease, neurology, and cardiovascular disease. He holds board seats at Daktari Diagnostics, electroCore, and Prophecy; and is a board observer at Asuragen and Genome Dx.
Dr. Rubin joined Merck in 2007 as Director of Franchise and Portfolio Management. His primary responsibilities were to oversee the operational support of all Merck Research Laboratories (MRL) disease area franchises and provide portfolio management support to MRL Oncology, including the development of franchise strategies, scenario planning, and portfolio valuation. He joined Merck from Cognia Corporation where he was CEO and President, and helped to develop it into one of the pioneer bioinformatics products company. Previously, he was at The Wilkerson Group/IBM Global Services in a Strategic Management position supporting pharma, biotech, and diagnostics companies.
Dr. Rubin holds a Ph.D. from Temple University in Molecular Biology and a B.A. from SUNY Binghamton in Biology. He was a National Institutes of Health and American Cancer Society Post-Doctoral fellow at Harvard Medical School where he worked on the Ubiquitin Proteasome Pathway. He also received training in post-graduate business at Harvard University.
Misti Ushio, Ph.D., Director
Dr. Ushio is CEO of TARA Biosystems. Prior to TARA Biosystems, Dr. Ushio was Chief Strategy Officer and Managing Director of Harris & Harris Group, which she joined in 2007. Prior to joining Harris & Harris Group, Dr. Ushio worked for Merck & Co. for over 10 years in the BioProcess Research & Development group, which focused on vaccines and biologics development. She also worked as a Technology Licensing Officer at Columbia University.
Dr. Ushio currently serves or has served on the boards of Accelerator-NYC, AgBiome, Enumeral Biomedical, Lodo Therapeutics, Petra Pharma, OpGen, Senova Systems and SynGlyco.
Her past investments include BioVex (acquired by Amgen), TetraVitae (acquired by Eastman) and Ancora Pharmaceuticals (acquired by Corden Pharma).
She graduated from Johns Hopkins University (B.S., Chemical Engineering), Lehigh University (M.S., Chemical Engineering) and University College London (Ph.D., Biochemical Engineering).